{
    "name": "bevacizumab",
    "comment": "Rx",
    "other_names": [
        "Avastin",
        "Mvasi",
        "bevacizumab-awwb",
        "Zirabev",
        "bevacizumab-bvzr",
        "Alymsys",
        "bevacizumab-maly",
        "bevacizumab-adcd",
        "Vegzelma"
    ],
    "classes": [
        "Antineoplastics",
        "Monoclonal Antibody",
        "Antineoplastics",
        "VEGF Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/avastin-mvasi-bevacizumab-342257",
    "pregnancy": {
        "common": [
            "Based on findings from animal studies and its mechanism of action, drug may cause fetal harm in pregnant women",
            "Limited postmarketing reports describe cases of fetal malformations with bevacizumab use in pregnancy; however, these reports are insufficient to determine drug associated risks"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, IV administration of bevacizumab to pregnant rabbits every 3 days during organogenesis at doses ~1-10 times the clinical dose of 10 mg/kg produced fetal resorptions, decreased maternal and fetal weight gain and multiple congenital malformations including corneal opacities and abnormal ossification of the skull and skeleton including limb and phalangeal defects",
                    "Animal models link angiogenesis and VEGF and VEGF Receptor 2 (VEGFR2) to critical aspects of female reproduction, embryofetal development, and postnatal development"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise pregnant women of the potential risk to a fetus",
                    "Advise female patients of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of bevacizumab"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Inform females of reproductive potential of the risk of ovarian failure prior to starting; long term effects of bevacizumab exposure on fertility are unknown"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available on the presence of bevacizumab in human milk, the effects on the breast fed infant, or the effects on milk production",
            "Human IgG is present in human milk, but published data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts",
            "Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 6 months after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Bevacizumab products can result in minor hemorrhage, most commonly Grade 1 epistaxis; and serious, and in some cases fatal, hemorrhagic events",
                "Serious, sometimes fatal, arterial thromboembolic events (ATE) including cerebral infarction, transient ischemic attacks, myocardial infarction, angina, and a variety of other ATE; discontinue bevacizumab for severe ATE",
                "Increased risk of venous thromboembolic events (VTE) reported in patients treated with bevacizumab for cervical cancer; discontinue bevacizumab for life-threatening VTE",
                "Monitor blood pressure and treat hypertension; increased risk for severe hypertension; temporarily suspend treatment; discontinue if hypertensive crisis or hypertensive encephalopathy",
                "Increased relative risk for heart failure has been associated with therapy",
                "Posterior reversible encephalopathy syndrome (PRES) reported (0.5%); discontinue if PRES develops",
                "Proteinuria reported; temporarily suspend treatment for ≥2 g proteinuria/24 hr; discontinue if nephrotic syndrome occurs (incidence <1%)",
                "Evaluation for presence of varices recommended within 6 months of initiation of HCC therapy; there is lack of clinical data to support safety in patients with variceal bleeding within 6 months prior to treatment, untreated or incompletely treated varices with bleeding, or high risk of bleeding because these patients were excluded from clinical trials in HCC",
                "Do not administer to patients with recent history of hemoptysis of 1/2 teaspoon or more of red blood; discontinue in patients who develop a Grades 3-4 hemorrhage",
                "Risk of ovarian failure reported especially in premenopausal women receiving bevacizumab in combination with mFOLFOX chemotherapy compared to mFOLFOX alone; inform females of reproductive potential of the risk of ovarian failure prior to starting treatment",
                "Based on its mechanism of action and findings from animal studies, may cause fetal harm when administered to pregnant women (see Pregnancy)",
                "Infusion-related reactions may occur and include hypertension, hypertensive crises associated with neurologic signs and symptoms, wheezing, oxygen desaturation, Grade 3 hypersensitivity, anaphylactoid/anaphylactic reactions, chest pain, headaches, rigors, and diaphoresis; stop infusion if severe and administer appropriate therapy",
                "Not indicated for use with anthracycline-based chemotherapy; incidence of Grade≥3 left ventricular dysfunction was 1% in patients receiving bevacizumab compared to 0.6% of patients receiving chemotherapy alone"
            ],
            "specific": [
                {
                    "type": "Wound healing",
                    "description": [
                        "Impairs wound healing; discontinue before elected surgeries and do not initiate following surgery; withhold therapy until adequate wound healing",
                        "Discontinue treatment in patients with wound healing complications requiring medical intervention",
                        "Withhold for at least 28 days prior to elective surgery",
                        "Do not administer for at least 28 days following surgery and until the wound is fully healed",
                        "Necrotizing fasciitis including fatal cases, has been reported, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation",
                        "Safety of resumption of bevacizumab products after resolution of wound healing complications has not been established"
                    ]
                },
                {
                    "type": "GI perforation and fistula formation",
                    "description": [
                        "Serious and sometimes fatal GI perforation occurs",
                        "Serious and sometimes fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites occurs at a higher incidence in bevacizumab-treated patients compared to controls",
                        "Patients who develop a gastrointestinal vaginal fistula may also have a bowel obstruction and require surgical intervention, as well as a diverting ostomy",
                        "Avoid in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "bevacizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "bevacizumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "bevacizumab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "bevacizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "bevacizumab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of bevacizumab by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, bevacizumab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sunitinib",
            "description": {
                "common": "bevacizumab, sunitinib. Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of bevacizumab and sunitinib is not recommended. Cases of microangiopathic hemolytic anemia (MAHA) have been reported.  ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "bevacizumab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "bevacizumab decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daunorubicin",
            "description": {
                "common": "bevacizumab, daunorubicin. Other (see comment). Use Caution/Monitor. \nComment: Potential for increased risk of cardiotoxicity (CHF). Caution is warranted."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "bevacizumab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and bevacizumab both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin",
            "description": {
                "common": "bevacizumab, doxorubicin. Other (see comment). Use Caution/Monitor. \nComment: Potential for increased risk of cardiotoxicity (CHF). Caution is warranted."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin liposomal",
            "description": {
                "common": "bevacizumab, doxorubicin liposomal. Other (see comment). Use Caution/Monitor. \nComment: Potential for increased risk of cardiotoxicity (CHF). Caution is warranted."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of bevacizumab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epirubicin",
            "description": {
                "common": "bevacizumab, epirubicin. Other (see comment). Use Caution/Monitor. \nComment: Potential for increased risk of cardiotoxicity (CHF). Caution is warranted."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idarubicin",
            "description": {
                "common": "bevacizumab, idarubicin. Other (see comment). Use Caution/Monitor. \nComment: Potential for increased risk of cardiotoxicity (CHF). Caution is warranted."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan",
            "description": {
                "common": "bevacizumab, irinotecan. Other (see comment). Use Caution/Monitor. \nComment: Potential for increased risk of diarrhea and neutropenia during concomitant administration of  bevacizumab and irinotecan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "bevacizumab, irinotecan liposomal. Other (see comment). Use Caution/Monitor. \nComment: Potential for increased risk of diarrhea and neutropenia during concomitant administration of  bevacizumab and irinotecan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "bevacizumab will decrease the level or effect of paclitaxel by  Other (see comment). Use Caution/Monitor. Possible decreased paclitaxel exposure after 4 treatment cycles of bevacizumab in combination with paclitaxel and carboplatin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "bevacizumab will decrease the level or effect of paclitaxel protein bound by  Other (see comment). Use Caution/Monitor. Possible decreased paclitaxel exposure after 4 treatment cycles of bevacizumab in combination with paclitaxel and carboplatin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and bevacizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and bevacizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sorafenib",
            "description": {
                "common": "bevacizumab, sorafenib. Other (see comment). Use Caution/Monitor. \nComment: Monitor for development of hand-foot skin reactions during combination therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and bevacizumab both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "72-80"
        },
        {
            "name": "Nausea",
            "percent": "53-58"
        },
        {
            "name": "Arthralgia",
            "percent": "33-41"
        },
        {
            "name": "Diarrhea",
            "percent": "38-40"
        },
        {
            "name": "Headache",
            "percent": "26-34"
        },
        {
            "name": "Hypertension",
            "percent": "24-32"
        },
        {
            "name": "Epistaxis",
            "percent": "30-31"
        },
        {
            "name": "Dyspnea",
            "percent": "26-28"
        },
        {
            "name": "Stomatitis",
            "percent": "19-25"
        },
        {
            "name": "Pain in extremity",
            "percent": "19-25"
        },
        {
            "name": "Muscular weakness",
            "percent": "13-15"
        },
        {
            "name": "Dysarthria",
            "percent": "10-12"
        },
        {
            "name": "Neutropenia",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "31"
        },
        {
            "name": "Hypertension",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "19"
        },
        {
            "name": "Peripheral sensory neuropathy",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "18"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "13"
        },
        {
            "name": "Proteinuria",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "12"
        },
        {
            "name": "Infection",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "11"
        },
        {
            "name": "Palmar",
            "percent": "2-4"
        },
        {
            "name": "plantar erythrodysesthesia",
            "percent": "11"
        },
        {
            "name": "Grade",
            "percent": "82"
        },
        {
            "name": "Fatigue",
            "percent": "72"
        },
        {
            "name": "Nausea",
            "percent": "58"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "55"
        },
        {
            "name": "Epistaxis",
            "percent": "49"
        },
        {
            "name": "Headache",
            "percent": "42"
        },
        {
            "name": "Hypertension",
            "percent": "38-39"
        },
        {
            "name": "Diarrhea",
            "percent": "35"
        },
        {
            "name": "Decreased appetite",
            "percent": "33"
        },
        {
            "name": "Abdominal pain",
            "percent": "31"
        },
        {
            "name": "stomatitis",
            "percent": "30"
        },
        {
            "name": "vomiting",
            "percent": "28"
        },
        {
            "name": "Hyperglycemia",
            "percent": "27"
        },
        {
            "name": "Dyspnea",
            "percent": "26"
        },
        {
            "name": "Arthralgia",
            "percent": "21"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "7-10"
        },
        {
            "name": "Cough",
            "percent": "5"
        },
        {
            "name": "Insomnia",
            "percent": "10"
        },
        {
            "name": "back pain",
            "percent": "9"
        },
        {
            "name": "Nasal mucosal disorder",
            "percent": "8"
        },
        {
            "name": "Epistaxis",
            "percent": "8"
        },
        {
            "name": "Rhinorrhea",
            "percent": "7"
        },
        {
            "name": "Hyperkalemia",
            "percent": null
        },
        {
            "name": "Hemorrhoids",
            "percent": null
        },
        {
            "name": "Sinus congestion",
            "percent": null
        },
        {
            "name": "Gingival bleeding",
            "percent": null
        }
    ]
}